Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force

  1. Kenneth Lin, MD;
  2. Robert Lipsitz, MD, MPH;
  3. Therese Miller, DrPH; and
  4. Supriya Janakiraman, MD, MPH
  1. From the Center for Primary Care, Prevention, and Clinical Partnerships, Agency for Healthcare Research and Quality, Rockville, Maryland.
    1. Figure.
      View larger version:
      Figure. Analytic framework for screening for prostate cancer.
    2. Appendix Figure 1.
      View larger version:
      Appendix Figure 1. Key question 1: stages of article review.

      RCT = randomized, controlled trial.

    3. Appendix Figure 2.
      View larger version:
      Appendix Figure 2. Key question 2: stages of article review.
    4. Appendix Figure 3.
      View larger version:
      Appendix Figure 3. Key question 3: stages of article review.

    Summary for Patients

    • Summaries for Patients:Screening for Prostate Cancer with Prostate-Specific Antigen Testing: U.S. Preventive Services Task Force Recommendations Ann Intern Med August 5, 2008 149:I-37
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med August 5, 2008 vol. 149 no. 3 192-199
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)
      1. Summary for Patients
    6. Recommendation Summary

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues